Scorpion Therapeutics
Boston, MA · Founded 2020 · CIK 0001811858 · Biotech · Acquired
Precision oncology inhibitors targeting PI3Ka for genomically defined cancers
scorpiontx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $297M
- 3 Form D · Jul 2024
- 27 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 3 granted · 37 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2019202020212022202320242025
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $24,681,250 | |
| Private capital raised | Form D · SEC | $146,999,977 | |
| Private capital raised | Form D · SEC | $125,694,186 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2837 | OMNI BIO PHARMACEUTICAL, INC. | — | $28M |
| 2838 | ReAlta Life Sciences, Inc. | — | $94M |
| 2839 | Verve Therapeutics | — | $94M |
| 2840 | Scorpion Therapeutics | — | $297M |
| 2841 | VASCULAR BIOSCIENCES, INC. | — | — |
| 2842 | EXPRESSION THERAPEUTICS, LLC | — | — |
| 2843 | CinCor Pharma | — | $143M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Jeffrey AlbersDirector
- Peter Campisi, Jr.Executive Officer
- Mark ChaoExecutive Officer
- Shelley ChuDirector
- Andrew FedderExecutive Officer
- Keith FlahertyDirector
- Jean-Francois FormelaDirector
- Adam FriedmanDirector · Executive Officer
- Gary GlickDirector · Executive Officer
- Arjun GoyalDirector
- Erica JacksonExecutive Officer
- Oleg NodelmanDirector
- Brian PiperExecutive Officer
- Saurabh SahaDirector
- Otello StampacchiaDirector
- Darrin StuartExecutive Officer
- Amanda ValentinoExecutive Officer
Patents
- Combination Therapy For Treating Cancerapplication
- Methods For Treating Cancerapplication
- PI3K-ALPHA Inhibitors For The Treatment Of Cancerapplication
- Methods For Treating Cancerapplication
- Methods Of Synthesizing Egfr Inhibitorsapplication
- Methods For Treating Cancergranted
- Compounds That Inhibit PI3K Isoform Alpha And Methods For Treating Cancerapplication
- Urea Derivatives Which Can Be Used To Treat Cancerapplication
- Methods For Treating Cancergranted
- Methods For Treating Cancergranted
- Crystalline Forms Of A PI3K Inhibitor And Uses Of Sameapplication
- Processes Of Preparing PI3K Inhibitorsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.